NxCare is asked by the Electronic Retailing Self-Regulatory Program to discontinue product superiority claims and modify weight-loss related performance claims for its Methyl Ripped fat burner product in a decision announced Dec. 8. Claims reviewed by ERSP include: "Bodybuilding's strongest fat burner" and "Methyl Ripped's formula goes to work quickly obliterating fat." The watchdog program determined NxCare's submitted testing results did not adequately support "all reasonable interpretations" communicated by the claims and recommended modifying or discontinuing them. ERSP also recommends NxCare increase the text size of disclosure language accompanying consumer testimonials to be made "more clear and conspicuous"...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.
Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.
Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.
